SECOND SIGHT MEDICAL PRODUCTS INC EYES Cash Flow

Second sight medical products inc (EYES)

CashFlow / TTM

Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Cash flows from operating activities:
Net loss
-33,592	-34,582	-35,520	-35,041	-35,094	-33,645	-31,839	-30,721	-28,516	-31,477	-33,250	-34,911	-33,179	-28,282	-24,459	-25,829	-20,018	-28,121	-31,100	-28,767	-35,201	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property and equipment
397	399	409	423	435	441	450	455	457	466	458	446	432	415	380	433	335	300	292	201	279	0	0	0
Stock-based compensation
2,925	3,243	3,434	3,202	3,589	3,752	3,780	4,088	3,784	3,607	3,601	3,402	3,367	3,350	3,308	3,632	2,687	2,277	1,712	879	1,475	0	0	0
Non-cash lease expense
17	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of discount on convertible notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Non-cash interest accrued on convertible notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,952	0	0	0
Bad debt expense
-	-	-	-	-	-	-	-	-142	-61	31	206	258	0	0	0	-	-	-	-	-	-	-	-
Excess inventory reserve
-	-	-	-	619	-1,204	-1,589	-2,502	-3,106	386	1,749	4,015	4,728	0	0	0	-	-	-	-	-	-	-	-
Impairment charge
-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock issued for services
-	-	-	-	109	176	241	262	262	261	261	262	272	0	0	0	-	-	-	-	-	-	-	-
Common stock issuable for services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Common stock issuable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Changes in operating assets and liabilities:
Accounts receivable
-48	-821	2	249	-1,220	463	-391	-415	1,413	230	376	166	-955	-681	-335	125	793	561	749	113	239	0	0	0
Inventories
347	-90	595	1,985	1,178	-831	-1,034	-2,856	-3,868	-2,131	-2,556	-1,859	-10	238	2,064	3,303	2,488	2,938	2,763	2,467	3,375	0	0	0
Prepaid expenses and other assets
-1,070	-114	181	353	605	41	-77	-21	71	-147	78	-74	-378	-170	-528	-69	127	-90	475	502	556	0	0	0
Accounts payable
-213	-419	34	-6	554	675	580	707	-419	163	-43	180	446	150	340	194	197	111	-369	15	199	0	0	0
Accrued expenses
-472	245	616	377	80	-349	-219	-178	331	654	563	626	44	-190	-162	228	656	715	1,138	664	749	0	0	0
Accrued compensation expenses
8	-498	-241	5	80	696	627	471	1,013	214	149	-87	-469	-196	42	332	707	0	0	0	-	-	-	-
Accrued compensation expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Accrued clinical trial expenses
-226	-201	-36	76	153	311	441	299	150	68	81	40	13	-2	41	112	127	66	19	-2	-2	0	0	0
Contract liabilities
169	446	295	60	121	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred grant revenue
-	-	-	-	-	-	-	-	-	0	0	52	-	-597	-644	-282	-278	177	531	519	531	0	0	0
Deferred grant revenue
-	-	-	-	-	-	-	-	-	-	-	-1,630	-	0	0	0	-	-	-	-	-	-	-	-
Net cash used in operating activities
-27,629	-27,974	-28,971	-30,182	-29,810	-28,793	-26,016	-24,126	-23,947	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred grant revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-26,582	-	-15,746	-16,706	-12,440	-17,092	0	0	0
Cash flows from investing activities:
Purchases of property and equipment
493	413	211	132	163	228	230	244	265	265	346	483	490	590	765	857	762	695	570	468	560	0	0	0
Proceeds from money market funds
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Proceeds from money market funds
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0
Net cash used in investing activities
-493	-413	-211	-132	-163	-228	-230	-244	-265	1,555	7,622	-6,424	-490	3,270	1,726	23,357	17,517	-21,398	-23,671	-30,332	-25,948	0	0	0
Proceeds from exercise of common stock options and warrants
-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Cash flows from financing activities:
Net proceeds from sale of common stock and warrants
34,505	41,396	46,365	56,343	25,936	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from rights offering
-	-	-	-	-	-	-	-	-	0	0	39,171	-	0	0	0	-	-	-	-	-	-	-	-
Net proceeds from sale of common stock
-	-	-	-	-	-	-	-	20,772	0	0	0	-	-	-	-	-	-	-	-	-	0	0	0
Proceeds from repayment of note receivable
-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Proceeds from exercise of options, warrants and employee stock purchase plan options
-	-	-	-	665	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of options and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Payment of employment taxes related to stock option exercises
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Proceeds from exercise of options and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Repurchase of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Net cash provided by financing activities
34,989	41,882	46,851	56,993	26,601	20,645	15,677	5,486	21,168	20,032	20,031	39,754	20,452	20,706	20,903	3,145	2,759	36,578	37,971	43,100	43,804	0	0	0
Effect of exchange rate changes on cash and cash equivalents
-11	0	0	-11	-	-	-84	7	8	8	89	11	23	-16	-89	-79	-107	-141	-132	-161	-207	0	0	0
Net increase (decrease)
-	-	0	26,668	-	-	-10,653	-18,877	-3,036	-2,654	2,224	7,711	-5,085	9	-223	-160	-380	-708	-2,539	167	557	0	0	0
Common stock issued in connection with finder fees paid on private placements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	451	0	0	0
Fair value of stock options issued for services rendered in connection with rights offering
-	-	-	-	-	-	-	-	20	20	20	46	53	0	0	0	-	-	-	-	-	-	-	-